MedTrace Logo

Safety and Tolerability of Coenzyme Q10 in Hemodialysis Patients

NCT00908297 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-04-24

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of the dietary supplement Coenzyme Q10 in hemodialysis patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Coenzyme Q10

By mouth (wafer) once daily for duration of study (8 weeks). Dose escalation: * 300 mg for two weeks * 600 mg for two weeks * 1200 mg for two weeks * 1800 mg for final two weeks

Sponsors & Collaborators

Principal Investigators

  • Jonathan Himmelfarb, MD · University of Washington - Kidney Research Institute

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-10-31
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00908297 on ClinicalTrials.gov